Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14–Mutant NSCLC

Before the recent approval of capmatinib in the United States, crizotinib was recommended by the National Comprehensive Cancer Network guidelines for the treatment of advanced MET exon 14 mutant (METex14) NSCLC. The role of capmatinib in patients exhibiting disease progression after treatment with crizotinib is not well established. Here, we describe a patient with metastatic METex14 NSCLC who, after an initial systemic response to crizotinib,...